TAUi001-A-1

JPH2

General#

Cell Line

hPSCreg Name TAUi001-A-1
Alternative name(s)
JPH2
Cell line type Human induced pluripotent stem cell (hiPSC)
Last update 17th April 2020
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Tampere University (TAU)
Derivation country Finland

External Databases

BioSamples SAMEA6880675
Cellosaurus CVCL_ZA78
CLO CLO_0102830

General Information

* Is the cell line readily obtainable for third parties?
Yes
Cell line can only be used in: Fit4purpose-OOC project
Research: allowed
Clinical: not allowed
Commercial: allowed
Subclone of

Donor Information#

General Donor Information

Sex male
Ethnicity Caucasian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
hypertrophic cardiomyopathy
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Asymmetric Septal Hypertrophies
  • Hypertrophic Obstructive Cardiomyopathies
  • Cardiomyopathy, hypertrophic
  • Subvalvular Stenosis, Idiopathic Hypertrophic
  • Hypertrophic Obstructive Cardiomyopathy
  • HYPERTR OBSTR CARDIOMYOP
  • hyper. obst. cardiomyopathy
  • SUBVALV STENOSIS
  • HCM - Hypertrophic cardiomyopathy
  • IDIOPATHIC HYPERTROPHIC SUBVALV STENOSIS
  • Obstructive Cardiomyopathy, Hypertrophic
  • Hypertrophies, Asymmetric Septal
  • Hypertrophic Cardiomyopathies
  • Cardiomyopathies, Hypertrophic Obstructive
  • Hypertrophic cardiomyopathy (disorder)
  • HOCM - Hypertrophic obstructive cardiomyopathy
  • Primary hypertrophic cardiomyopathy
  • Idiopathic Hypertrophic Subvalvular Stenosis
  • IHSS
  • primary hypertrophic cardiomyopathy (disorder) [Ambiguous]
  • Idiopathic Hypertrophic Subaortic Stenosis
  • Obstructive cardiomyopathy
  • SUBVALV STENOSIS IDIOPATHIC HYPERTROPHIC
  • Hypertrophy, Asymmetric Septal
  • Hypertrophic obstructive cardiomyopathy (disorder)
  • Septal Hypertrophy, Asymmetric
  • Cardiomyopathies, Hypertrophic
  • IHSSs
  • hypertrophic myocardiopathy
  • Cardiomyopathy, Hypertrophic Obstructive
  • HCM
  • Obstructive Cardiomyopathies, Hypertrophic
  • Asymmetric Septal Hypertrophy
  • Septal Hypertrophies, Asymmetric
  • hypertrophic subaortic stenosis
  • obstructive hypertrophic cardiomyopathy
  • hypertrophic obstructive cardiomyopathy
  • hypertrophic cardiomyopathy
show more synonyms
Genetic variants
JPH2 (target)
q13.12.
NM_020433.5:c.482C>A
NP_065166.2:p.(Thr161Lys)
Heterozygous
JPH2 mutation c.482C>A (p.T161K)

Karyotyping (Donor)

Has the donor karyotype been analysed?
No

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA6880674

Ethics#

Also have a look at the ethics information for the parental line TAUi001-A .
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation#

General

The source cell information can be found in the parental cell line TAUi001-A.

Reprogramming method

Vector type Non-integrating
Vector Episomal
Genes
Is reprogramming vector detectable?
No

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions#

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzymatically
Versene
CO2 Concentration 5 %
Medium mTeSR™ 1
Supplements
Pen/Strep %
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
No

Characterisation#

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR FACS Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
SOX2
Yes
NANOG
Yes
ZFP42 (REX-1)
Yes
C-MYC
Yes
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
Marker Expressed
SOX17
Yes
AFP
Yes
Protocol or reference
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
Marker Expressed
KDR
Yes
ACTC1 / alpha cardiac actinin
Yes
Protocol or reference
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
Marker Expressed
SOX1
Yes
PAX6
Yes
Protocol or reference

Genotyping#

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
No

Other Genotyping (Cell Line)

Genetic Modification#

Genetic modifications not related to a disease
JPH2 (target)
Isogenic modification
q13.12.
NM_020433.5:c.482A>C
NP_065166.2:p.(Lys161Thr)
Heterozygous
Repaired